Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Larkin

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)Cristina Suárez, James M G Larkin, Poulam Patel, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancerJ Zujewski, I D Horak, C J Bol, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective studyPatricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2021
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic MelanomaAmod A Sarnaik, Omid Hamid, Nikhil I Khushalani, et al.
Arthritis Care & Research|May 8, 2012
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohortS C Shiboski, C H Shiboski, L A Criswell, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)Cristina Suárez, James M G Larkin, Poulam Patel, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancerJ Zujewski, I D Horak, C J Bol, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective studyPatricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2021
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic MelanomaAmod A Sarnaik, Omid Hamid, Nikhil I Khushalani, et al.
Arthritis Care & Research|May 8, 2012
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohortS C Shiboski, C H Shiboski, L A Criswell, et al.
Pageof 13